医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ZRG Partners Life Sciences Hiring Index Shows Double Digit Increases Over 2013

2014年10月28日 AM01:00
このエントリーをはてなブックマークに追加


 

WEST ORANGE, N.J.

ZRG Partners, Inc. announces the results of its third quarter Global Life Sciences Hiring Index. The Index posts its highest score in nearly five years, even with the European markets taking a small hiring hit this quarter.

ZRG Managing Director David Fortier commented, “The robust hiring activity across most sectors and functions reflects optimism, particularly in North America, about future growth prospects for the industry. The year-over-year increases are very encouraging and it is good to see some resurgence in the medical device sector. The data for technical roles correlates with our observations of a highly competitive market for top talent in these functions.”

About ZRG Partners
ZRG Partners, Inc. is a global authority on talent management issues in the Life Sciences, Pharmaceutical and Medical Device markets. ZRG provides its clients with specialized global market expertise in executive recruitment, consulting and advisory work with a focus on data and analytics to drive great business decisions.

The Global Life Sciences Hiring Index analysis utilizes a proprietary algorithm that looks at hiring within selected benchmark companies in three distinct segments. The companies in the Index generate over $630 billion in revenues and employ over 1.5 million people globally. ZRG Partners conducts extensive direct market research in developing the data that drives the Index.

For more information about ZRG please go to www.zrgpartners.com

CONTACT

ZRG Partners, Inc.
Adam
El Din
, +41-22-319-3304
European President and Global Practice
Head of Life Sciences
or
David
Fortier
, +1-508-366-5800 x227
Managing Director

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • AnHeart Therapeutics Announces Formation of Scientific Advisory Board
  • Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
  • Celltrion用于治疗COVID-19的单克隆抗体瑞丹维单抗(CT-P59)成为韩国食品药品安全部(MFDS)首个核准用于治疗COVID-19的药物
  • Celltrionのモノクローナル抗体治療薬、Regdanvimab(CT-P59)は、韓国食品医薬品安全庁(MFDS)からCOVID-19感染症治療薬として初めて承認された。
  • Fewer Australians report a sense of belonging at work when compared to pre-pandemic